Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer

Overview of attention for article published in Drug Design, Development and Therapy, February 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

policy: 1 policy source
twitter: 1 X user

patent: 1 patent
wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 98 Dimensions

Readers on

mendeley: 166 Mendeley

Summary Policy documents X Patents Wikipedia Dimensions citations

So far, Altmetric has seen 1 X post from an account with 792 followers.

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2212 advanced breast cancer https://t.co/F6iOPz73kq

Reply Repost Favourite